Detalles de la búsqueda
1.
Determining the optimal interval between neoadjuvant radiochemotherapy and surgery in rectal cancer: a retrospective cohort study.
Int J Colorectal Dis
; 38(1): 154, 2023 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37261511
2.
Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial.
Br J Cancer
; 126(6): 874-880, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34937947
3.
Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
Oncologist
; 26(3): e394-e402, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33219618
4.
A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience.
Oncologist
; 26(5): e769-e779, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33687747
5.
Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results.
BMC Cancer
; 20(1): 1164, 2020 Nov 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33246428
6.
A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features.
BMC Cancer
; 15: 60, 2015 Feb 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-25886378
7.
Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer.
BMC Cancer
; 15: 59, 2015 Feb 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-25886275
8.
Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study.
BMC Cancer
; 15: 327, 2015 Apr 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-25925749
9.
Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment.
Biomed Pharmacother
; 176: 116857, 2024 Jun 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38850664
10.
Recommendations for the optimal management of peritoneal metastases in patients with colorectal cancer: a TTD and GECOP-SEOQ expert consensus statement.
Clin Transl Oncol
; 25(12): 3378-3394, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37140736
11.
Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402.
J Natl Cancer Inst
; 115(12): 1497-1505, 2023 12 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37405857
12.
Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study.
Clin Cancer Res
; 29(2): 379-388, 2023 01 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36074154
13.
Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre network.
Mol Oncol
; 17(9): 1908-1916, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37097008
14.
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
Oncologist
; 17(1): 15-25, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22234633
15.
SEOM-GECOD clinical guideline for unknown primary cancer (2021).
Clin Transl Oncol
; 24(4): 681-692, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35320504
16.
Spatial Immunology in Liver Metastases from Colorectal Carcinoma according to the Histologic Growth Pattern.
Cancers (Basel)
; 14(3)2022 Jan 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-35158957
17.
Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study.
Oncologist
; 16(5): 614-20, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21467148
18.
Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial.
Clin Cancer Res
; 27(10): 2890-2898, 2021 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33727257
19.
Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer.
Chemotherapy
; 56(2): 142-6, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20407241
20.
Short-Course Radiotherapy in Locally Advanced Rectal Cancer.
Clin Transl Gastroenterol
; 11(6): e00162, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32568477